Celadon Pharmaceuticals PLC (CEL:LSE) Annual Income Statement ()
CEL:LSE Quarterly Financials ()
Frequently Asked Questions About Celadon Pharmaceuticals PLC (CEL:LSE) Stock
Celadon Pharmaceuticals PLC's (CEL:LSE) last reported annual revenue was GBX 75000.00.
Celadon Pharmaceuticals PLC's (CEL:LSE) annual revenue growth rate based on the revenue reported in the past 5 years is : -96.22%
Celadon Pharmaceuticals PLC's(CEL:LSE) is not profitable as of its last reported annual financials.
The net profit margin for Celadon Pharmaceuticals PLC's(CEL:LSE) from its laster reported year is -9520.00%
The return on equity (ROE) for Celadon Pharmaceuticals PLC's(CEL:LSE) from its last reported annual financials is : -190.71%
The return on assets (ROA) for Celadon Pharmaceuticals PLC's(CEL:LSE) from its last reported annual financials is : -34.40%
The return on invested capital (ROIC) for Celadon Pharmaceuticals PLC's(CEL:LSE) from its last reported annual financials is : -104.03%
The Debt to Equity ratio for Celadon Pharmaceuticals PLC's(CEL:LSE) from its last reported annual financials is : 0.44%
The dividend yield for Celadon Pharmaceuticals PLC's(CEL:LSE) from its laster reported year is 0.00%
Celadon Pharmaceuticals PLC's(CEL:LSE) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CEL:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
